Home › Compare › RVXCF vs GBDC

RVXCF vs GBDC: Dividend Comparison 2026

RVXCF yields 2500.00% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RVXCF wins by $80609755856.52M in total portfolio value
10 years
RVXCF
RVXCF
● Live price
2500.00%
Share price
$0.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80609755877.37M
Annual income
$74,729,580,081,858,750.00
Full RVXCF calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — RVXCF vs GBDC

📍 RVXCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRVXCFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RVXCF + GBDC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
RVXCF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RVXCF
Annual income on $10K today (after 15% tax)
$212,500.00/yr
After 10yr DRIP, annual income (after tax)
$63,520,143,069,579,940.00/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, RVXCF beats the other by $63,520,143,055,596,820.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RVXCF + GBDC for your $10,000?

RVXCF: 50%GBDC: 50%
100% GBDC50/50100% RVXCF
Portfolio after 10yr
$40304877949.11M
Annual income
$37,364,790,049,154,744.00/yr
Blended yield
92.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

RVXCF
No analyst data
Altman Z
-94.1
Piotroski
1/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RVXCF buys
0
GBDC buys
0
No recent congressional trades found for RVXCF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRVXCFGBDC
Forward yield2500.00% ✓11.86%
Annual dividend / share$2.00 ✓$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1% ✓
Portfolio after 10y$80609755877.37M ✓$20.85M
Annual income after 10y$74,729,580,081,858,750.00 ✓$16,450,733.83
Total dividends collected$80198875900.38M ✓$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: RVXCF vs GBDC ($10,000, DRIP)

YearRVXCF PortfolioRVXCF Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$260,700$250,000.00$12,492$1,791.70+$248.2K → RVXCF
2$6,370,070$6,091,121.50$16,527$3,160.58+$6.35M → RVXCF
3$145,912,632$139,096,656.81$23,588$5,904.90+$145.89M → RVXCF
4$3,133,830,814$2,977,704,297.75$37,141$11,901.65+$3133.79M → RVXCF
5$63,122,812,060$59,769,613,088.96$66,205$26,463.38+$63122.75M → RVXCF
6$1,192,683,724,131$1,125,142,315,226.76$137,452$66,612.65+$1192683.59M → RVXCF
7$21,144,559,711,004$19,868,388,126,183.19$342,372$195,298.53+$21144559.37M → RVXCF
8$351,818,906,448,043$329,194,227,557,269.44$1,053,292$686,954.33+$351818905.39M → RVXCF
9$5,495,491,397,671,320$5,119,045,167,771,913.00$4,111,439$2,984,416.95+$5495491393.56M → RVXCF
10$80,609,755,877,367,070$74,729,580,081,858,750.00$20,849,974$16,450,733.83+$80609755856.52M → RVXCF

RVXCF vs GBDC: Complete Analysis 2026

RVXCF — Stock

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.

Full RVXCF Calculator →

GBDC — BDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this RVXCF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RVXCF vs SCHDRVXCF vs JEPIRVXCF vs ORVXCF vs KORVXCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.